Diabetic Macular Edema - Pipeline Review, H2 2018

  • ID: 4592436
  • Report
  • 231 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Abpro
  • Ampio Pharmaceuticals Inc
  • Coherus BioSciences Inc
  • Formycon AG
  • Mabion SA
  • Pfizer Inc
  • MORE
Diabetic Macular Edema - Pipeline Review, H2 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Macular Edema - Pipeline Review, H2 2018, provides an overview of the Diabetic Macular Edema (Metabolic Disorders) pipeline landscape.

Diabetic macular edema (DME) occurs when blood vessels in the retina of patients with diabetes begin to leak into the macula, the part of the eye responsible for detailed central vision. Common symptoms of DME are blurry vision, floaters, double vision, and eventually blindness if it goes untreated. Risk factors include age and diabetes.

Report Highlights:

This latest pipeline guide Diabetic Macular Edema - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Diabetic Macular Edema (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Macular Edema (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Macular Edema and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 5, 19, 7, 2, 35 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Diabetic Macular Edema (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Macular Edema (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Diabetic Macular Edema (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diabetic Macular Edema (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diabetic Macular Edema (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Macular Edema (Metabolic Disorders)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diabetic Macular Edema (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diabetic Macular Edema (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abpro
  • Ampio Pharmaceuticals Inc
  • Coherus BioSciences Inc
  • Formycon AG
  • Mabion SA
  • Pfizer Inc
  • MORE
Introduction

Diabetic Macular Edema - Overview

Diabetic Macular Edema - Therapeutics Development

Diabetic Macular Edema - Therapeutics Assessment

Diabetic Macular Edema - Companies Involved in Therapeutics Development

Diabetic Macular Edema - Drug Profiles

Diabetic Macular Edema - Dormant Projects

Diabetic Macular Edema - Discontinued Products

Diabetic Macular Edema - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Diabetic Macular Edema, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Diabetic Macular Edema - Pipeline by Abpro, H2 2018

Diabetic Macular Edema - Pipeline by Aciont Inc, H2 2018

Diabetic Macular Edema - Pipeline by Acucela Inc, H2 2018

Diabetic Macular Edema - Pipeline by Aerie Pharmaceuticals Inc, H2 2018

Diabetic Macular Edema - Pipeline by Aldeyra Therapeutics Inc, H2 2018

Diabetic Macular Edema - Pipeline by Allergan Plc, H2 2018

Diabetic Macular Edema - Pipeline by Allgenesis Biotherapeutics Inc, H2 2018

Diabetic Macular Edema - Pipeline by Ampio Pharmaceuticals Inc, H2 2018

Diabetic Macular Edema - Pipeline by Araim Pharmaceuticals Inc, H2 2018

Diabetic Macular Edema - Pipeline by Boehringer Ingelheim GmbH, H2 2018

Diabetic Macular Edema - Pipeline by Cell Medica Ltd, H2 2018

Diabetic Macular Edema - Pipeline by Celon Pharma SA, H2 2018

Diabetic Macular Edema - Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, H2 2018

Diabetic Macular Edema - Pipeline by Clearside BioMedical Inc, H2 2018

Diabetic Macular Edema - Pipeline by Coherus BioSciences Inc, H2 2018

Diabetic Macular Edema - Pipeline by Daiichi Sankyo Co Ltd, H2 2018

Diabetic Macular Edema - Pipeline by Elasmogen Ltd, H2 2018

Diabetic Macular Edema - Pipeline by Exonate Ltd, H2 2018

Diabetic Macular Edema - Pipeline by EyeGate Pharmaceuticals Inc, H2 2018

Diabetic Macular Edema - Pipeline by EyePoint Pharmaceuticals Inc, H2 2018

Diabetic Macular Edema - Pipeline by Eyevensys SAS, H2 2018

Diabetic Macular Edema - Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Diabetic Macular Edema - Pipeline by Formycon AG, H2 2018

Diabetic Macular Edema - Pipeline by Gene Signal International SA, H2 2018

Diabetic Macular Edema - Pipeline by Genmab A/S, H2 2018

Diabetic Macular Edema - Pipeline by Graybug Vision Inc, H2 2018

Diabetic Macular Edema - Pipeline by Isarna Therapeutics GmbH, H2 2018

Diabetic Macular Edema - Pipeline by Kalvista Pharmaceuticals Inc, H2 2018

Diabetic Macular Edema - Pipeline by Kowa Co Ltd, H2 2018

Diabetic Macular Edema - Pipeline by Lupin Ltd, H2 2018

Diabetic Macular Edema - Pipeline by Mabion SA, H2 2018

Diabetic Macular Edema - Pipeline by Momenta Pharmaceuticals Inc, H2 2018

Diabetic Macular Edema - Pipeline by Novartis AG, H2 2018

Diabetic Macular Edema - Pipeline by Ocular Therapeutix Inc, H2 2018

Diabetic Macular Edema - Pipeline by Oculis ehf, H2 2018

Diabetic Macular Edema - Pipeline by OcuNexus Therapeutics Inc, H2 2018

Diabetic Macular Edema - Pipeline by Ohr Pharmaceutical Inc, H2 2018

Diabetic Macular Edema - Pipeline by Pfizer Inc, H2 2018

Diabetic Macular Edema - Pipeline by Profarma, H2 2018

Diabetic Macular Edema - Pipeline by Protheragen Inc, H2 2018

Diabetic Macular Edema - Pipeline by Regeneron Pharmaceuticals Inc, H2 2018

Diabetic Macular Edema - Pipeline by Rezolute Inc, H2 2018

Diabetic Macular Edema - Pipeline by SciFluor Life Sciences LLC, H2 2018

Diabetic Macular Edema - Pipeline by Senju Pharmaceutical Co Ltd, H2 2018

Diabetic Macular Edema - Pipeline by Stealth BioTherapeutics Inc, H2 2018

Diabetic Macular Edema - Pipeline by ThromboGenics NV, H2 2018

Diabetic Macular Edema - Pipeline by Unity Biotechnology Inc, H2 2018

Diabetic Macular Edema - Pipeline by Verseon Corp, H2 2018

Diabetic Macular Edema - Pipeline by Xbrane Biopharma AB, H2 2018

Diabetic Macular Edema - Dormant Projects, H2 2018

Diabetic Macular Edema - Dormant Projects, H2 2018 (Contd..1), H2 2018

Diabetic Macular Edema - Dormant Projects, H2 2018 (Contd..2), H2 2018

Diabetic Macular Edema - Discontinued Products, H2 2018

List of Figures

Number of Products under Development for Diabetic Macular Edema, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Abpro
  • Aciont Inc
  • Acucela Inc
  • Aerie Pharmaceuticals Inc
  • Aldeyra Therapeutics Inc
  • Allergan Plc
  • Allgenesis Biotherapeutics Inc
  • Ampio Pharmaceuticals Inc
  • Araim Pharmaceuticals Inc
  • Boehringer Ingelheim GmbH
  • Cell Medica Ltd
  • Celon Pharma SA
  • Chengdu Kanghong Pharmaceuticals Group Co Ltd
  • Clearside BioMedical Inc
  • Coherus BioSciences Inc
  • Daiichi Sankyo Co Ltd
  • Elasmogen Ltd
  • Exonate Ltd
  • EyeGate Pharmaceuticals Inc
  • EyePoint Pharmaceuticals Inc
  • Eyevensys SAS
  • F. Hoffmann-La Roche Ltd
  • Formycon AG
  • Gene Signal International SA
  • Genmab A/S
  • Graybug Vision Inc
  • Isarna Therapeutics GmbH
  • Kalvista Pharmaceuticals Inc
  • Kowa Co Ltd
  • Lupin Ltd
  • Mabion SA
  • Momenta Pharmaceuticals Inc
  • Novartis AG
  • Ocular Therapeutix Inc
  • Oculis ehf
  • OcuNexus Therapeutics Inc
  • Ohr Pharmaceutical Inc
  • Pfizer Inc
  • Profarma
  • Protheragen Inc
  • Regeneron Pharmaceuticals Inc
  • Rezolute Inc
  • SciFluor Life Sciences LLC
  • Senju Pharmaceutical Co Ltd
  • Stealth BioTherapeutics Inc
  • ThromboGenics NV
  • Unity Biotechnology Inc
  • Verseon Corp
  • Xbrane Biopharma AB
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll